Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arnoud Templeton

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Onkologie|October 10, 2009
Primary manifestation of small lymphocytic lymphoma in the prostateMartin Fehr, Arnoud Templeton, Sergio Cogliatti, et al.
Breast Cancer Research and Treatment|September 8, 2012
Management of small HER2 overexpressing tumoursArnoud Templeton, Alberto Ocaña, Boštjan Seruga, et al.
Complementary Medicine Research|October 27, 2017
[Erfahrungen am Lebensende: Eine Umfrage bei Ärzten und Pflegenden eines Spitals für anthroposophisch erweiterte Medizin]Sabine Klein, Sara Kohler, Daniel Krüerke, et al.
Breast Cancer Research and Treatment|February 22, 2016
Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancerAlberto Ocaña, Javier Pérez-Peña, Laura Díez-González, et al.
Cancer Medicine|September 30, 2016
The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanomaLeila Khoja, Eshetu G Atenafu, Arnoud Templeton, et al.
European Urology|July 12, 2011
Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteomeMartin Kälin, Igor Cima, Ralph Schiess, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 1, 2023
Early response monitoring during [<sup>177</sup>Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry studyMoritz C Neubauer, Guillaume P Nicolas, Andreas Bauman, et al.
Onkologie|May 27, 2010
Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02)Thomas Ruhstaller, Arnoud Templeton, Karin Ribi, et al.
International Journal of Cancer|August 14, 2015
Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteriaNatalie Turner, Hui-Li Wong, Arnoud Templeton, et al.
The Oncologist|April 7, 2019
Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC)Aaron R Hansen, Ian F Tannock, Arnoud Templeton, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Onkologie|October 10, 2009
Primary manifestation of small lymphocytic lymphoma in the prostateMartin Fehr, Arnoud Templeton, Sergio Cogliatti, et al.
Breast Cancer Research and Treatment|September 8, 2012
Management of small HER2 overexpressing tumoursArnoud Templeton, Alberto Ocaña, Boštjan Seruga, et al.
Complementary Medicine Research|October 27, 2017
[Erfahrungen am Lebensende: Eine Umfrage bei Ärzten und Pflegenden eines Spitals für anthroposophisch erweiterte Medizin]Sabine Klein, Sara Kohler, Daniel Krüerke, et al.
Breast Cancer Research and Treatment|February 22, 2016
Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancerAlberto Ocaña, Javier Pérez-Peña, Laura Díez-González, et al.
Cancer Medicine|September 30, 2016
The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanomaLeila Khoja, Eshetu G Atenafu, Arnoud Templeton, et al.
European Urology|July 12, 2011
Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteomeMartin Kälin, Igor Cima, Ralph Schiess, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 1, 2023
Early response monitoring during [<sup>177</sup>Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry studyMoritz C Neubauer, Guillaume P Nicolas, Andreas Bauman, et al.
Onkologie|May 27, 2010
Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02)Thomas Ruhstaller, Arnoud Templeton, Karin Ribi, et al.
International Journal of Cancer|August 14, 2015
Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteriaNatalie Turner, Hui-Li Wong, Arnoud Templeton, et al.
The Oncologist|April 7, 2019
Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC)Aaron R Hansen, Ian F Tannock, Arnoud Templeton, et al.
Pageof 3